Information Provided By: 
Fly News Breaks for November 5, 2018
ZGNX
Nov 5, 2018 | 05:01 EDT
Piper Jaffray analyst Danielle Brill started Zogenix with an Overweight rating and $72 price target. While the cardiac safety implications are a "clear overhang" for the shares, ZX008's benefits in Dravet syndrome outweigh the risks, Brill tells investors in a research note. The analyst expects FDA approval to drive shares higher in 2019.
News For ZGNX From the Last 2 Days
There are no results for your query ZGNX
